<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 12, 2018 (HealthDay News) — For older cancer patients undergoing major cancer surgery, propofol-based general anesthesia may reduce the incidence of delayed neurocognitive recovery versus sevoflurane-based general anesthesia, according to a study published in the September issue of the British Journal of Anesthesia<\/i>.<\/p>\n
Y. Zhang, from the Peking University First Hospital in China, and colleagues randomized 392 older adults who were scheduled to undergo major cancer surgery to receive propofol- or sevoflurane-based general anesthesia. Cognitive function was assessed with a battery of neuropsychological tests before and one week after surgery (379 patients completed one-week neuropsychological testing). A total of 59 age-and education-matched non-surgical controls were recruited and underwent cognitive function testing at comparable time intervals.<\/p>\n
The researchers found that, compared with the sevoflurane group, the propofol group had significantly lower incidence of delayed neurocognitive recovery at one week (14.8 versus 23.2 percent; odds ratio, 0.577). The two groups did not differ in terms of safety outcomes.<\/p>\n
“Compared with sevoflurane-based general anesthesia, propofol-based general anesthesia reduced the incidence of delayed neurocognitive recovery in elderly patients at one week after major cancer surgery,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n